Meds
Roche Holding AG's (ROG.VX) eye disease drug Lucentis proved effective in helping to improve vision in patients suffering from a condition known as central retinal vein occlusion, Roche's Genentech unit said.
This was the second six-month, late-stage study of Lucentis for retinal vein occlusion to deliver statistically significant results showing vision improvement compared with a placebo.
The drug developed by Genentech, which was acquired by the Swiss drugmaker earlier this year, is currently approved to treat wet age-related macular degeneration -- the leading cause of blindness in the elderly.
Retinal vein occlusion, or RVO, is a common cause of vision loss that occurs when blood flow through a retinal vein becomes blocked, such as by a blood clot, causing fluid to build up and vision to cloud.
Doug
CDIstaffing.com